ArQule, Inc. (ARQL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule, Inc. (ARQL)

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	4/23/2010 12:27:27 PM
	of 545

anybody know the SEC-related story here???........ ASCO has granted formal Policy Exceptions for the following abstracts to allow limited information to be made publicly available in advance of the Annual Meeting due to Securities and Exchange Commission (SEC) requirements: SEC Exceptions: Abstract 8010 Lenalidomide maintenance after transplantation for myeloma. Abstract LBA4007 The AVAGAST trial: A randomized, double-blind, placebo-controlled, multicenter phase III study of capecitabine and cisplatin plus bevacizumab or placebo as first-line therapy in patients with advanced gastric cancer. Abstract LBA4507 Denosumab versus zoledronic acid for treatment of bone metastases in patients with castration-resistant prostate cancer. Abstract LBA1 Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. Abstract LBA4511 A randomized, double-blind, placebo controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrate-resistant prostate cancer (metCRPC): Survival results of CALGB 90401. Abstract LBA7502 Results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGPR-inhibitor naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next